Skip to content

Clinical study of body weight management with fasting in overweight and obese patients

Clinical study of body weight management with fasting in overweight and obese patients

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2500099520
Enrollment
Unknown
Registered
2025-03-25
Start date
2021-06-15
Completion date
Unknown
Last updated
2025-03-31

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Overweight and obesity

Interventions

The lifestyle intervention plus meal replacement (MR)-assisted intermittent fasting group:Participants in the MR group received a dietary intervention that included a 5:2 intermittent fasting regimen.
The lifestyle intervention alone:All participants were instructed to adhere to prescribed diets. Participants in LIA group consumed a calorie-restricted diet (1200-1400 kcal/d for men and 1000-1200 kc

Sponsors

Taizhou Hospital of Zhejiang Province Affiliated to Wenzhou Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 60 Years

Inclusion criteria

Inclusion criteria: We recruited participants aged 18-60 years with a stable weight change (± 4 kg) over the last three months, and met at least one of the following criteria: overweight with BMI >= 24 kg/m2, or fat mass percentage >=30% for women and >=25% for men, or waist circumference >=85 cm for women and >=90 cm for men.

Exclusion criteria

Exclusion criteria: 1. Cancer, liver and kidney dysfunction, acute cardiovascular and cerebrovascular disease, acute infectious disease, psychosis, bulimia nervoides, anorexia, gastrointestinal disease, or history of surgery within the past three months; 2. Pregnancy, lactation, oral contraceptives or hormone replacement therapy; 3. Endocrine or monogenic secondary obesity; 4. Artificial pacemakers. Participants who had started dieting to lose weight were excluded. Also excluded were participants who had taken glucose-lowering medications, psychotropic medications, weight-loss medications, or other medications known to affect body weight or energy metabolism during the 14 days before the study.

Design outcomes

Primary

MeasureTime frame
Body weight;

Secondary

MeasureTime frame
Body composition;Biochemical assays;

Countries

China

Contacts

Public ContactChen Yahong

Taizhou Hospital of Zhejiang Province Affiliated to Wenzhou Medical University

chenyh@enzemed.com+86 136 0665 5060

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026